ClinicalTrials.gg
CompletedNCT03407872Updated Jul 12, 2018

Safety and Pharmacokinetic Study of Inhaled Esketamine in Healthy Volunteers

A Phase 1 interventional study of Esketamine DPI and Esketamine DPI in Healthy Volunteers, sponsored by Celon Pharma SA. Completed at 1 site in Poland. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-12.

Sponsored by Celon Pharma SA · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The planned study is to determine the pharmacokinetic properties of Esketamine and safety assessment with inhaled Esketamine after different number of inhalations and different dosing sequences within three parts of the study.

Read the detailed description

This is to be one-centre, single ascending dose and double-blind placebo controlled multiple dose three part study of Esketamine DPI (dry powder inhaler) in healthy volunteers.

PART A is a single dose, open-label part with Esketamine DPI inhalations administered with dose escalation between cohorts.

PART B is a single dose, open-label part with Esketamine DPI inhalations administered in different dosing sequences with dose escalation between cohorts.

PART C is a multiple dose, double-blind, placebo-controlled part with Esketamine DPI inhalations administered in different cycles of treatment (with four dosing sequences within two weeks) with dose escalation between cohorts. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio.

Pharmacokinetic properties and safety of Esketamine DPI will be determined following different number of inhalations in PART A, different dosing sequences in PART B and different cycles of treatment in PART C.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Celon Pharma SA is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Caucasian female or male,
  • Age: 18-55 years old, inclusive,
  • Body-mass index (): ≥18.5 kg/m\^2 and \<29.9 kg/m\^2
  • Non-smoker and nonuser of tobacco products for at least 1 year before screening,
  • Physical examination without any abnormality,
  • Laboratory values not clinically significant,
  • Volunteer (or his/her partner) of willingness to use acceptable forms of .

Exclusion criteria

Exclusion Criteria:

  • Known allergy or to ketamine or its derivates and/or to any study product ,
  • Any known significant current or past acute or chronic disease or condition,
  • Participation in other clinical trial within 90 days preceding the screening,
  • Blood drawn within 30 days prior to inclusion to the study (more or equal to 300mL),
  • Positive results from pregnancy test for female participants,
  • Lactation in women participants,
  • Hypotension or hypertension in medical history,
  • Narcotic, alcohol addiction or abuse,
  • Participant who adhere to a special diet (e.g. low calories, vegetarian).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    PART A

    6 cohorts will receive single dose of Esketamine DPI administered with dose escalation between cohorts.

    Drug: Esketamine DPI

  • Experimental
    PART B

    4 cohorts will receive single dose of Esketamine DPI administered with dose escalation between cohorts.

    Drug: Esketamine DPI

  • Experimental
    PART C

    4 cohorts will receive multiple dose of Esketamine DPI in two weeks' time administered with dose escalation between cohorts.

    Drug: Esketamine DPI

  • Placebo comparator
    PART C placebo

    4 cohorts will receive multiple dose of matching placebo in two weeks' time.

    Drug: Placebo DPI

Interventions

  • DrugEsketamine DPI

    Participants will receive different number of consecutive Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts.

  • DrugEsketamine DPI

    Participants will receive different dosing sequences of Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A of the study. Dose: very low, low, medium, high.

  • DrugEsketamine DPI

    Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. There will be dose escalation between cohorts. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A and PART B of the study. Dose: very low, low, medium, high.

  • DrugPlacebo DPI

    Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio. In each cohort, number of placebo inhalations within a dosing sequence will correspond to number of Esketamine DPI inhalations.

06

What researchers measure

Primary outcomes

  1. Cmax - maximum Esketamine plasma concentration

    The maximum concentration of the Esketamine in plasma after drug administration, obtained directly from the measured concentrations.

    Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.

  2. AUC (0-24) - area under the Esketamine plasma concentration-time curve from time 0 to 24 hours after study drug administration

    The AUC(0-24) is a measure of total plasma exposure to the drug from time point zero to 24 hours after study drug administration.

    Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.

  3. Number of inhalations needed to achieve the assumed Esketamine antidepressive plasma concentration.

    Time frame: up to 24 hours after study drug administration in PART A

  4. Number of inhalations within dosing sequence needed to maintain the assumed Esketamine antidepressive plasma concentration.

    Time frame: up to 24 hours after study drug administration in PART B

Secondary outcomes

  1. AUC (0-inf) - area under the Esketamine plasma concentration-time curve from time 0 to infinity time

    The AUC(0-inf) is a measure of total plasma exposure to the drug from time point zero extrapolated to infinity.

    Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.

  2. Tmax - time to reach maximum Esketamine plasma concentration

    The Tmax is time to reach the maximum plasma concentration (Cmax), obtained directly from the actual sampling times.

    Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.

  3. Kel -elimination rate constant

    Kel will be estimated via linear regression of time versus log of concentration.

    Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.

  4. T1/2 - plasma elimination half-life for Esketamine

    T1/2 will be calculated as 0.693/Kel.

    Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.

  5. Cmax - maximum Esnorketamine plasma concentration

    The maximum concentration of the Esnorketamine in plasma after drug administration, obtained directly from the measured concentrations. Esnorketamine is Esketamine's main metabolite.

    Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.

  6. AUC (0-24) - area under the Esnorketamine plasma concentration-time curve from time 0 to 24 hours after study drug administration.

    The AUC(0-24) is a measure of total Esnorketamine plasma exposure to the metabolite from time point zero to 24 hours after study drug administration. Esnorketamine is Esketamine's main metabolite.

    Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.

  7. Tmax - time to reach maximum Esnorketamine plasma concentration.

    The Tmax is time to reach the maximum Esnorketamine plasma concentration (Cmax), obtained directly from the actual sampling times. Esnorketamine is Esketamine's main metabolite.

    Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.

  8. Number of participants with adverse events (AEs) and Serious Adverse Events (SAEs).

    Participants during hospitalization will be closely observed to assure maximal safety and to collect occurrence of all adverse event. To follow-up on all study participants telephone calls with a request for information regarding their health condition will be made. All adverse events will be collected with special attention to occurrence of psychotomimetic and dissociative effects after study drug administration.

    Time frame: up to 7 days in PART A and PART B of the study and up to 25 days in PART C of the study.

07

Study locations

1 site
  • BioResearch Group Sp. z o.o.
    Kajetany, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in May 2018, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2018
First posted
Jan 23, 2018
StartActual
Dec 9, 2017
Primary completionActual
May 20, 2018
CompletionActual
Jun 19, 2018
Last update
Jul 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03407872
Lead sponsor
Celon Pharma SA
Collaborators
National Center for Research and Development, Poland
Responsible party
Sponsor
First posted
Jan 23, 2018
Start date
Dec 9, 2017
Primary completion
May 20, 2018
Completion
Jun 19, 2018
Last update
Jul 12, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion